Ventana to Develop CDx for Genmab Cancer Drug | GenomeWeb

NEW YORK (GenomeWeb News) – Roche business Ventana today announced a companion diagnostic development deal for a Genmab antibody drug conjugate program.

Ventana will develop an immunohistochemistry CDx test for detecting tissue factor in patient tumor samples with the intent that the assay could be used as the screening test in clinical trials for Genmab's HuMax-TF-ADC, Ventana said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.